Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34

This stock price fluctuation was triggered by the company's announcement that its experimental cancer drug has been granted a patent by the Japan Patent Office. **Background of Drug Development and Market Positioning** This experimental drug belongs to the field of immunotherapy and aims to combat cancer cells by modulating the human immune system. Currently, the global cancer immunotherapy market continues to expand, with many biotechnology companies competing for market share. Japan, as a major global pharmaceutical market, is often seen as an important indicator of a drug's commercialization prospects due to its patent approval process. The granting of this patent may lay the foundation for AIM ImmunoTech's future expansion in the Asian market. **Patent Value and Commercialization Pathway** The patent protection period is 20 years, covering the drug's composition and specific application methods. Analysts point out that the granting of the patent not only enhances the company's intellectual property asset value but may also attract potential partners or acquirers. However, the drug is still in the experimental stage and must complete clinical trials and obtain regulatory approval before it can be marketed. The company's next steps include conducting more clinical studies to verify the drug's safety and efficacy. **Market Reaction and Investor Focus** Pre-market trading volume increased significantly, indicating a positive market response to the news. The biotechnology sector has recently been active overall, driven by progress in anti-cancer drug development, with several small biotech companies gaining market attention due to research breakthroughs. Investors will focus on the company's subsequent clinical progress and fundraising capabilities to assess its long-term value.